2022
Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
Buza N, Hui P. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma. Archives Of Pathology & Laboratory Medicine 2022, 146: 0. PMID: 35687792, DOI: 10.5858/arpa.2021-0547-oa.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaClinical trial criteriaHER2 gene amplificationTrial criteriaHER2 immunohistochemistrySerous carcinomaAnti-human epidermal growth factor receptor 2 (HER2) therapyClinical Oncology/CollegeHER2 testing algorithmHER2 FISHProspective clinical investigationHER2 IHC 2HER2/CEP17Gene amplificationContext of breastTherapeutic responseIHC 2HER2 amplificationAverage HER2Most tumorsClinical investigationImmunohistochemistryHER2 fluorescenceTumorsMonosomy 17
2021
Immunohistochemistry
Euscher E, Buza N, Hui P. Immunohistochemistry. Practical Anatomic Pathology 2021, 367-416. DOI: 10.1007/978-3-030-68608-6_15.Peer-Reviewed Original ResearchFemale genital tractGynecologic tractGynecologic tumorsHistologic featuresRare tumorPatient prognosisGenital tractTumor alterationsUseful adjunctPrimary siteTumor typesPossible treatmentImmunohistochemistryTumorsSame organDiagnostic toolProper classificationTractCurrent useTreatmentBroad spectrumPrognosisTherapySubtypesAdjunctNon-HPV-Associated Cervical Neoplasia
Quddus M, Ou J, Hui P. Non-HPV-Associated Cervical Neoplasia. Practical Anatomic Pathology 2021, 95-111. DOI: 10.1007/978-3-030-68608-6_4.Peer-Reviewed Original ResearchCervical adenocarcinomaHigh-risk human papilloma virusDaily practiceGestational trophoblastic tumorsHuman papilloma virusSquamous cell carcinomaUterine cervical carcinomaBiopsy/resectionTrophoblastic tumorCervical neoplasiaCell carcinomaCervical carcinomaDiagnostic challengeMetastatic tumorsPapilloma virusMalignant melanomaBenign lesionsTumorsHrHPVAdenocarcinomaCarcinomaSignificant percentagePathologistsHPVResection
2020
Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing
Chen PH, Hui P, Buza N. Bilateral Signet-ring Stromal Tumor of the Ovary: A Case Report With Next-generation Sequencing Analysis and FOXL2 Mutation Testing. International Journal Of Gynecological Pathology 2020, 39: 193-198. PMID: 30676431, DOI: 10.1097/pgp.0000000000000579.Peer-Reviewed Case Reports and Technical NotesConceptsSignet-ring stromal tumorStromal tumorsNext-generation sequencing analysisBilateral solid ovarian tumorsBilateral ovarian massesFOXL2 mutation testingSolid ovarian tumorSignet ring cell morphologySmooth muscle actinUnderlying genetic abnormalitiesPCR-Sanger sequencingNuclear beta-catenin expressionHandful of casesHeterogenous pathogenesisAbdominal distentionRectal bleedingTotal hysterectomyStromal neoplasmsOvarian massesOvarian tumorsCase reportBeta-catenin expressionSequencing analysisMuscle actinTumors
2018
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors
Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 116: 619-624. PMID: 30584090, PMCID: PMC6329978, DOI: 10.1073/pnas.1814027116.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAzepinesBRCA1 ProteinBRCA2 ProteinCell Line, TumorClass I Phosphatidylinositol 3-KinasesFemaleHumansMiceMutationNeoplasm MetastasisNeoplasm Recurrence, LocalOvarian NeoplasmsProteinsProto-Oncogene Proteins c-mycTriazolesTumor Suppressor Protein p53Xenograft Model Antitumor AssaysConceptsOvarian cancerWhole-exome sequencingC-myc amplificationRecurrent tumorsPrimary tumorBET inhibitorsChemotherapy-resistant diseaseRecurrent ovarian cancerLethal gynecologic malignancyBilateral ovarian cancerChemotherapy-resistant tumorsPrimary metastatic tumorsMutational landscapeSomatic mutationsFresh-frozen tumorsGynecologic malignanciesMetastatic tumorsPrimary cell linesC-MYC gainPIK3CA amplificationTranscoelomic metastasisTherapeutic targetPatientsMetastatic abilityTumorsGestational Trophoblastic Tumors: A Timely Review of Diagnostic Pathology
Hui P. Gestational Trophoblastic Tumors: A Timely Review of Diagnostic Pathology. Archives Of Pathology & Laboratory Medicine 2018, 143: 65-74. PMID: 30407075, DOI: 10.5858/arpa.2018-0234-ra.Peer-Reviewed Original ResearchConceptsGestational trophoblastic tumorsTrophoblastic tumorPersistent gestational trophoblastic neoplasiaPlacental site trophoblastic tumorAtypical placental site noduleEarly chemotherapeutic interventionPlacental site noduleEpithelioid trophoblastic tumorGestational trophoblastic neoplasiaClinical featuresGestational choriocarcinomaTrophoblastic neoplasiaHistologic characteristicsPathologic diagnosisClinical managementPrecursor lesionsHigh indexClinical practiceAccurate diagnosisTumorsChemotherapeutic interventionSurveillance programDistinct entityMolecular biomarkersDiagnostic recognitionFOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors
Buza N, Wong S, Hui P. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors. International Journal Of Gynecological Pathology 2018, 37: 305-315. PMID: 28700438, DOI: 10.1097/pgp.0000000000000426.Peer-Reviewed Original ResearchConceptsSex cord-stromal tumorsAdult granulosa cell tumorGranulosa cell tumorsOvarian sex cord-stromal tumorsCell tumorsReticulin patternFOXL2 mutationStaining patternSertoli-Leydig cell tumorFOXL2 mutation statusAbundant pale cytoplasmSingle institutional cohortThird of casesWild-type tumorsFOXL2 mutation analysisNegative tumorsPositive tumorsTumor sizeReticulin stainingType tumorsPale cytoplasmNuclear atypiaMutation statusPositive casesTumors
2017
Hormone producing gynecological tumors: pathologic entities and clinical significance
Boto AN, Hui P. Hormone producing gynecological tumors: pathologic entities and clinical significance. Expert Review Of Endocrinology & Metabolism 2017, 13: 9-24. PMID: 30063444, DOI: 10.1080/17446651.2018.1411799.Peer-Reviewed Original ResearchConceptsHormonal biomarkersGynecologic tumorsGynecologic neoplasmsOverproduction of hormonesAbnormal clinical manifestationsPatient treatment optionsGynecological organsNormal physiological settingsSerum hormonesClinical manifestationsGynecological tumorsTreatment optionsAbnormal elevationPathologic entityPathological diagnosisTherapeutic responseDisease progressionClinical significanceClinical utilityTreatment efficacyClinical monitoringHormonal productionHormonal productsTumorsHormoneFrequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis
Snir OL, DeJoseph M, Wong S, Buza N, Hui P. Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis. Modern Pathology 2017, 30: 1467-1475. PMID: 28664933, DOI: 10.1038/modpathol.2017.66.Peer-Reviewed Original ResearchConceptsMixed germ cell tumorGerm cell tumorsPure immature teratomaImmature teratomaCell tumorsMature teratomaGenetic zygosityMixed ovarian germ cell tumorOvarian germ cell tumorsOvarian immature teratomaImmature ovarian teratomaDifferent pathogenetic pathwaysMature cystic teratomaImmature teratoma componentsDifferent biological behaviorTeratoma componentsRate of homozygosityCystic teratomaOvarian teratomaTumor recurrenceCommon cellular originPathogenetic pathwaysGrade 2TumorsTeratoma
2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarboplatinCarcinomaCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell SurvivalDisease-Free SurvivalDNA Polymerase IIDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleHumansMicrosatellite InstabilityMiddle AgedMutationPoly-ADP-Ribose Binding ProteinsTumor Cells, CulturedConceptsBetter prognosisTumor cell linesInfiltration of CD4Number of CD4Platinum-based chemotherapyT lymphocyte infiltrationPD-1 receptorCell linesLow metastatic capabilityPOLE-mutated tumorsWild-type ECsEC cell linesLymphocyte infiltrationFavorable prognosisPD-1EC patientsType tumorsEnhanced immunogenicityT lymphocytesMolecular subtypesTumors correlatesChemotherapyMetastatic capabilityPrognosisTumorsMucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study
Snir OL, Buza N, Hui P. Mucinous epithelial tumours arising from ovarian mature teratomas: a tissue genotyping study. Histopathology 2016, 69: 383-392. PMID: 26952875, DOI: 10.1111/his.12959.Peer-Reviewed Original ResearchConceptsOvarian mucinous tumorsMucinous borderline tumorsMucinous tumorsBorderline tumorsMucinous carcinomaAssociated teratomaPrimary ovarian mucinous tumorsOvarian mucinous borderline tumorMucinous epithelial tumorsOvarian mature teratomaGerm cell originShort tandem repeat polymorphic lociTissue genotypingMetastatic tumorsMature teratomaEpithelial tumorsTeratomatous componentsTumor originDiagnostic utilityMetastatic onesCell originTumorsTeratomaSomatic cellsPolymorphic lociSarcomas and Related Mesenchymal Tumors
Tallini G, de Biase D, Hui P. Sarcomas and Related Mesenchymal Tumors. 2016, 487-506. DOI: 10.1007/978-3-319-19674-9_37.Peer-Reviewed Original ResearchManagement of patientsMesenchymal tumorsClinical managementMesenchymal lesionsPathological diagnosisTumor subsetsRecurrent chromosomal changesClinical practiceSarcomaTumor phenotypeMolecular pathologyRelative rarityNext-generation sequencingTumorsChromosomal changesDiagnosisNovel technical approachCytogenetics
2011
Persistent Trophoblastic Neoplasia
Hui P. Persistent Trophoblastic Neoplasia. Current Clinical Pathology 2011, 139-145. DOI: 10.1007/978-1-61779-394-3_9.Peer-Reviewed Original ResearchGestational trophoblastic neoplasiaPersistent trophoblastic neoplasiaTrophoblastic neoplasiaClinical treatment decisionsSerial hCGTrophoblastic tumorHistological diagnosisMolar pregnancyTissue diagnosisTreatment decisionsIndividual patientsNeoplasiaClinical termsPatientsMarker evaluationDiagnosisChemotherapySequelaePregnancyChoriocarcinomaHCGFIGOTumorsTumor-Like Trophoblastic Conditions
Hui P. Tumor-Like Trophoblastic Conditions. Current Clinical Pathology 2011, 147-159. DOI: 10.1007/978-1-61779-394-3_10.Peer-Reviewed Original ResearchPlacental site nodulePlacental site trophoblastic tumorEpithelioid trophoblastic tumorTrophoblastic tumorIntermediate trophoblastExaggerated placental site reactionNon-trophoblastic neoplasmsSquamous cell carcinomaPrior pregnancyCell carcinomaSite reactionsIncidental findingProliferative lesionsNeoplastic counterpartsImplantation sitesCytological featuresLesionsTumorsTrophoblastConcurrent gestationReactive conditionsClinicopathologicallyPregnancyReactive processCarcinomaGenetic Basis of Gestational Trophoblastic Disease
Hui P. Genetic Basis of Gestational Trophoblastic Disease. Current Clinical Pathology 2011, 41-55. DOI: 10.1007/978-1-61779-394-3_3.Peer-Reviewed Original ResearchGestational trophoblastic diseasePlacental site trophoblastic tumorEpithelioid trophoblastic tumorTrophoblastic tumorIntermediate trophoblastTrophoblastic diseaseExaggerated placental site reactionChorionic villous trophoblastPlacental site noduleUnique clinical settingGestational choriocarcinomaSite reactionsMalignant tumorsLesional cellsProliferative lesionsProliferative disordersTrophoblastic cellsVillous trophoblastBiomarker expressionClinical settingImplantation sitesTumorsUnique genetic factorsRecent linkage studiesComplete hydatidiformGestational Choriocarcinoma
Hui P. Gestational Choriocarcinoma. Current Clinical Pathology 2011, 127-137. DOI: 10.1007/978-1-61779-394-3_8.Peer-Reviewed Original ResearchGestational choriocarcinomaMalignant tumorsMethotrexate-based chemotherapyMortality of patientsDecidua of pregnancyHematogenous spreadCure rateFatal malignancyTrophoblastic diseaseChemotherapy managementAggressive formChoriocarcinomaChorial villiTumorsTumor cellsSarcomaDiseaseChemotherapyPatientsPregnancyDramatic decreaseMalignancyMortalityPlacentaDeciduaPrevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early‐Stage Ovarian Cancer
Steffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T, Mor G. Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early‐Stage Ovarian Cancer. Journal Of Oncology 2011, 2011: 620523. PMID: 21904548, PMCID: PMC3166719, DOI: 10.1155/2011/620523.Peer-Reviewed Original ResearchEarly-stage ovarian cancerCancer stem cellsEOC stem cellsOvarian cancer stem cellsProgression-free survivalEpithelial ovarian cancer stem cellsNumber of CD44Ovarian cancerShorter progression-free survivalStem cellsOvarian cancer tumorsPredictors of diseaseTreatment selectionCancer tumorsCancerCD44RecurrenceTumorsSurvivalCellsHigher numberPatientsCK18PrevalenceChemoresistanceMinimal Uterine Serous Carcinoma With Extrauterine Spread
Flynn C, Hui P. Minimal Uterine Serous Carcinoma With Extrauterine Spread. AJSP Review And Reports 2011, 16: 104-107. DOI: 10.1097/pcr.0b013e31821734fe.Peer-Reviewed Original ResearchMinimal uterine serous carcinomaUterine serous carcinomaSerous carcinomaEndometrial polypsSerous endometrial intraepithelial carcinomaEndometrial intraepithelial carcinomaExtrauterine diseaseConventional serous carcinomasExtrauterine spreadAbdominal carcinomatosisIntraepithelial carcinomaMüllerian carcinomasImmunohistochemical profileMutant p53 proteinPatient's diseaseCarcinomaDiseaseP53 proteinPolypsPresumed originCarcinomatosisPostmenopausalPatientsUterusTumors
2010
Nonepithelial Tumor of Ovary
Chhieng D, Hui P. Nonepithelial Tumor of Ovary. Current Clinical Pathology 2010, 173-191. DOI: 10.1007/978-1-60761-164-6_11.Peer-Reviewed Original ResearchEpithelial Neoplasms of Ovary
Chhieng D, Hui P. Epithelial Neoplasms of Ovary. Current Clinical Pathology 2010, 145-172. DOI: 10.1007/978-1-60761-164-6_10.Peer-Reviewed Original ResearchSurface epithelial tumorsGerm cell tumorsCell tumorsEpithelial tumorsOvarian neoplasmsPrimary ovarian neoplasmsSex cord tumorSex cord differentiationPrimary ovarian tumorsOvarian stromal cellsTransitional cell tumorsBreast primaryHistological subtypesOvarian tumorsClinical behaviorClinicopathological stagingEpithelial neoplasmsSecondary tumorsClear cellsTheca cellsGranulosa cellsCell originTumorsLeydig cellsStromal cells